1
|
Lang JM, Sedgeman LR, Cai L, Layne JD, Wang Z, Pan C, Lee R, Temel RE, Lusis AJ. Dietary and Pharmacologic Manipulations of Host Lipids and Their Interaction With the Gut Microbiome in Non-human Primates. Front Med (Lausanne) 2021; 8:646710. [PMID: 34513856 PMCID: PMC8426918 DOI: 10.3389/fmed.2021.646710] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 08/03/2021] [Indexed: 12/12/2022] Open
Abstract
The gut microbiome influences nutrient processing as well as host physiology. Plasma lipid levels have been associated with the microbiome, although the underlying mechanisms are largely unknown, and the effects of dietary lipids on the gut microbiome in humans are not well-studied. We used a compilation of four studies utilizing non-human primates (Chlorocebus aethiops and Macaca fascicularis) with treatments that manipulated plasma lipid levels using dietary and pharmacological techniques, and characterized the microbiome using 16S rDNA. High-fat diets significantly reduced alpha diversity (Shannon) and the Firmicutes/Bacteroidetes ratio compared to chow diets, even when the diets had different compositions and were applied in different orders. When analyzed for differential abundance using DESeq2, Bulleidia, Clostridium, Ruminococcus, Eubacterium, Coprocacillus, Lachnospira, Blautia, Coprococcus, and Oscillospira were greater in both chow diets while Succinivibrio, Collinsella, Streptococcus, and Lactococcus were greater in both high-fat diets (oleic blend or lard fat source). Dietary cholesterol levels did not affect the microbiome and neither did alterations of plasma lipid levels through treatments of miR-33 antisense oligonucleotide (anti-miR-33), Niemann-Pick C1-Like 1 (NPC1L1) antisense oligonucleotide (ASO), and inducible degrader of LDLR (IDOL) ASO. However, a liver X receptor (LXR) agonist shifted the microbiome and decreased bile acid levels. Fifteen genera increased with the LXR agonist, while seven genera decreased. Pseudomonas increased on the LXR agonist and was negatively correlated to deoxycholic acid, cholic acid, and total bile acids while Ruminococcus was positively correlated with taurolithocholic acid and taurodeoxycholic acid. Seven of the nine bile acids identified in the feces significantly decreased due to the LXR agonist, and total bile acids (nmol/g) was reduced by 62%. These results indicate that plasma lipid levels have, at most, a modest effect on the microbiome, whereas bile acids, derived in part from plasma lipids, are likely responsible for the indirect relationship between lipid levels and the microbiome.
Collapse
Affiliation(s)
- Jennifer M. Lang
- Departments of Medicine, Microbiology and Human Genetics, University of California, Los Angeles, Los Angeles, CA, United States
| | - Leslie R. Sedgeman
- Department of Medicine, Division of Cardiology, University of California, Los Angeles, Los Angeles, CA, United States
| | - Lei Cai
- Cardiovascular Research Center, University of Kentucky, Lexington, KY, United States
| | - Joseph D. Layne
- Cardiovascular Research Center, University of Kentucky, Lexington, KY, United States
- Cardiovascular and Metabolic Diseases, Novartis Institutes for Biomedical Research, Cambridge, MA, United States
| | - Zhen Wang
- Department of Physiology, School of Basic Medical Sciences, Shandong University, Jinan, China
| | - Calvin Pan
- Departments of Medicine, Microbiology and Human Genetics, University of California, Los Angeles, Los Angeles, CA, United States
| | - Richard Lee
- Ionis Pharmaceuticals, Carlsbad, CA, United States
| | - Ryan E. Temel
- Cardiovascular and Metabolic Diseases, Novartis Institutes for Biomedical Research, Cambridge, MA, United States
- Department of Physiology, University of Kentucky, Lexington, KY, United States
| | - Aldons J. Lusis
- Departments of Medicine, Microbiology and Human Genetics, University of California, Los Angeles, Los Angeles, CA, United States
| |
Collapse
|
2
|
Gatineau E, Arthur G, Poupeau A, Nichols K, Spear BT, Shelman NR, Graf GA, Temel RE, Yiannikouris FB. The prorenin receptor and its soluble form contribute to lipid homeostasis. Am J Physiol Endocrinol Metab 2021; 320:E609-E618. [PMID: 33459178 PMCID: PMC7988779 DOI: 10.1152/ajpendo.00135.2020] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Obesity is associated with alterations in hepatic lipid metabolism. We previously identified the prorenin receptor (PRR) as a potential contributor to liver steatosis. Therefore, we aimed to determine the relative contribution of PRR and its soluble form, sPRR, to lipid homeostasis. PRR-floxed male mice were treated with an adeno-associated virus with thyroxine-binding globulin promoter-driven Cre to delete PRR in the liver [liver PRR knockout (KO) mice]. Hepatic PRR deletion did not change the body weight but increased liver weights. The deletion of PRR in the liver decreased peroxisome proliferator-activated receptor gamma (PPARγ) and triglyceride levels, but liver PRR KO mice exhibited higher plasma cholesterol levels and lower hepatic low-density lipoprotein receptor (LDLR) and Sortilin 1 (SORT1) proteins than control (CTL) mice. Surprisingly, hepatic PRR deletion elevated hepatic cholesterol, and up-regulated hepatic sterol regulatory element-binding protein 2 (SREBP2) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA-R) genes. In addition, the plasma levels of sPRR were significantly higher in liver PRR KO mice than in controls. In vitro studies in HepG2 cells demonstrated that sPRR treatment upregulated SREBP2, suggesting that sPRR could contribute to hepatic cholesterol biosynthesis. Interestingly, PRR, total cleaved and noncleaved sPRR contents, furin, and Site-1 protease (S1P) were elevated in the adipose tissue of liver PRR KO mice, suggesting that adipose tissue could contribute to the circulating pool of sPRR. Overall, this work supports previous works and opens a new area of investigation concerning the function of sPRR in lipid metabolism and adipose tissue-liver cross talk.NEW & NOTEWORTHY Hepatic PRR and its soluble form, sPRR, contribute to triglyceride and cholesterol homeostasis and hepatic inflammation. Deletion of hepatic PRR decreased triglyceride levels through a PRR-PPARγ-dependent mechanism but increased hepatic cholesterol synthesis through sPRR-medicated upregulation of SREBP-2. Our study highlighted a new paradigm of cross talk between the liver and the adipose tissue involving cholesterol and sPRR.
Collapse
Affiliation(s)
- Eva Gatineau
- Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky
| | - Gertrude Arthur
- Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky
| | - Audrey Poupeau
- Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky
| | - Kellea Nichols
- Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky
| | - Brett T Spear
- Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, Kentucky
| | - Nathan R Shelman
- Department of Pathology & Laboratory Medicine, University of Kentucky, Lexington, Kentucky
| | - Gregory A Graf
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky
| | - Ryan E Temel
- Cardiovascular Research Center and Department of Physiology, University of Kentucky, Lexington, Kentucky
| | | |
Collapse
|
3
|
An amperometric cholesterol biosensor based on immobilization of cholesterol oxidase onto titanium dioxide nanoparticles. SENSORS INTERNATIONAL 2021. [DOI: 10.1016/j.sintl.2021.100111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
4
|
Beaufrère H, Gardhouse S, Ammersbach M. Lipoprotein characterization in Quaker parrots (Myiopsitta monachus) using gel-permeation high-performance liquid chromatography. Vet Clin Pathol 2020; 49:417-427. [PMID: 32966641 DOI: 10.1111/vcp.12895] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 01/01/2020] [Accepted: 02/14/2020] [Indexed: 01/08/2023]
Abstract
BACKGROUND Lipid accumulation disorders, such as atherosclerosis and hepatic lipidosis, are common in psittacine birds and associated with various dyslipidemias. Gel-permeation high-performance liquid chromatography (GP-HPLC) is a reference method for advanced lipoprotein profiling based on particle size separation, followed by an analysis of lipid contents. OBJECTIVES The objectives were to (a) characterize Quaker parrot lipoproteins using a commercial GP-HPLC method (Liposearch panel), and (b) obtain preliminary information on the reliability of the Friedewald formula for low-density lipoprotein-cholesterol (LDL-C) measurements. METHODS Plasma samples were collected from 12 fasted healthy Quaker parrots. Cholesterol concentrations, triglyceride concentrations, particle sizes, and particle numbers were determined by GP-HPLC for four classes and 20 sub-fractions of lipoproteins. The LDL-C concentrations obtained using the Friedewald formula and direct measurements were compared with Bland-Altman plots. Alternate formulas were determined using multiple linear regression. RESULTS High-density lipoprotein (HDL) was the predominant lipoprotein in Quaker parrots, and most particles were of medium-to-small sizes belonging to two sub-fractions (average size, 10.6 nm). LDL was the second most common lipoprotein and included large-to-small particles belonging to three sub-fractions (average size, 24.9 nm). Very-low-density lipoproteins (VLDL) and portomicrons were present in low concentrations. The Friedewald formula underestimated LDL-C concentrations with a significant bias of 0.44 mmol/L. An alternate formula was proposed: LDL-C = 0.75*Non-HDL-C. CONCLUSIONS GP-HPLC allowed unprecedented characterization of plasma lipoproteins in Quaker parrots. Characterizing psittacine lipoprotein is useful for validation and interpretation of routine clinical tests as well as for use in epidemiologic and experimental research on psittacine lipid accumulation disorders.
Collapse
Affiliation(s)
- Hugues Beaufrère
- Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada
| | - Sara Gardhouse
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA
| | | |
Collapse
|
5
|
Hirowatari Y, Yoshida H. Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography. J Atheroscler Thromb 2019; 26:1027-1040. [PMID: 31548491 PMCID: PMC6927812 DOI: 10.5551/jat.rv17037] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 08/20/2019] [Indexed: 12/15/2022] Open
Abstract
Separation analysis of lipoprotein classes have various methods, including ultracentrifugation, electrophoresis, and gel permeation chromatography (GPC). All major lipoprotein classes can be separated via ultracentrifugation, but performing the analysis takes a long time. Low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL), and very low-density lipoprotein (VLDL) in patient samples cannot be sufficiently separated via electrophoresis or GPC. Thus, we established a new method [anion-exchange high-performance liquid chromatography (AEX-HPLC)] by using HPLC with an AEX column containing nonporous gel and an eluent containing chaotropic ions. AEX-HPLC can separate five lipoprotein fractions of high-density lipoprotein (HDL), LDL, IDL, VLDL, and others in human serum, which can be used in substitution for ultracentrifugation method. The method was also approved for clinical use in the public health-care insurance in Japan in 2014. Furthermore, we developed an additional method to measure cholesterol levels of the four leading lipoprotein fractions and two subsequent fractions (i.e., chylomicron and lipoprotein(a)). We evaluated the clinical usefulness of AEX-HPLC in patients with coronary heart disease (CHD), diabetes, and kidney disease and in healthy volunteers. Results indicate that the cholesterol levels in IDL and VLDL measured by AEX-HPLC may be useful risk markers of CHD or diabetes. Furthermore, we developed another new method for the determination of alpha-tocopherol (AT) in lipoprotein classes, and this method is composed of AEX-HPLC for the separation of lipoprotein classes and reverse-phase chromatography to separate AT in each lipoprotein class. The AT levels in LDL were significantly correlated with the lag time to copper ion-induced LDL oxidation, which is an index of oxidation resistance. The application of AEX-HPLC to measure various substances in lipoproteins will be clinically expected in the future.
Collapse
Affiliation(s)
- Yuji Hirowatari
- Laboratory Science, Department of Health Science, Saitama Prefectural University Saitama, Japan
| | - Hiroshi Yoshida
- Department of Laboratory Medicine, The Jikei University Kashiwa Hospital, Chiba, Japan
| |
Collapse
|
6
|
Li J, Pijut SS, Wang Y, Ji A, Kaur R, Temel RE, van der Westhuyzen DR, Graf GA. Simultaneous Determination of Biliary and Intestinal Cholesterol Secretion Reveals That CETP (Cholesteryl Ester Transfer Protein) Alters Elimination Route in Mice. Arterioscler Thromb Vasc Biol 2019; 39:1986-1995. [PMID: 31462090 PMCID: PMC6761010 DOI: 10.1161/atvbaha.119.312952] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVE Determine the impact of CETP (cholesteryl ester transfer protein) on the route of cholesterol elimination in mice. Approach and Results: We adapted our protocol for biliary cholesterol secretion with published methods for measuring transintestinal cholesterol elimination. Bile was diverted and biliary lipid secretion maintained by infusion of bile acid. The proximal small bowel was perfused with bile acid micelles. In high-fat, high-cholesterol-fed mice, the presence of a CETP transgene increased biliary cholesterol secretion at the expense of transintestinal cholesterol elimination. The increase in biliary cholesterol secretion was not associated with increases in hepatic SR-BI (scavenger receptor BI) or ABCG5 (ATP-binding cassette G5) ABCG8. The decline in intestinal cholesterol secretion was associated with an increase in intestinal Niemann-Pick disease, type C1, gene-like 1 mRNA. Finally, we followed the delivery of HDL (high-density lipoprotein) or LDL (low-density lipoprotein) cholesteryl esters (CE) from plasma to bile and intestinal perfusates. HDL-CE favored the biliary pathway. Following high-fat feeding, the presence of CETP directed HDL-CE away from the bile and towards the intestine. The presence of CETP increased LDL-CE delivery to bile, whereas the appearance of LDL-CE in intestinal perfusate was near the lower limit of detection. CONCLUSIONS Biliary and intestinal cholesterol secretion can be simultaneously measured in mice and used as a model to examine factors that alter cholesterol elimination. Plasma factors, such as CETP, alter the route of cholesterol elimination from the body. Intestinal and biliary cholesterol secretion rates are independent of transhepatic or transintestinal delivery of HDL-CE, whereas LDL-CE was eliminated almost exclusively in the hepatobiliary pathway.
Collapse
Affiliation(s)
- Jianing Li
- Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY
- Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY
| | - Sonja S Pijut
- Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY
| | - Yuhuan Wang
- Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY
| | - Ailing Ji
- Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY
| | - Rupinder Kaur
- Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY
| | - Ryan E Temel
- Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY
- Department of Physiology, University of Kentucky, Lexington, KY
| | - Deneys R van der Westhuyzen
- Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY
- Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY
| | - Gregory A Graf
- Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY
- Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY
- Barnstable Brown Center for Diabetes and Obesity, University of Kentucky, Lexington, KY
| |
Collapse
|
7
|
Estridge TB, Dey AB, Reidy C, Yu X, Zhang Y, Hartley M, Milligan PL, Jin N, Kowala MC, Leohr JK, Fretland AJ, Mabry TE, Luffer-Atlas D, Luo MJ. Identification of 4-Aminopyrazolopyrimidine Metabolite That May Contribute to the Hypolipidemic Effects of LY2584702 in Long Evans Diet-Induced Obese Rats. J Pharmacol Exp Ther 2017; 362:108-118. [PMID: 28465372 DOI: 10.1124/jpet.117.240242] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Accepted: 04/26/2017] [Indexed: 12/28/2022] Open
Abstract
LY2584702 is an inhibitor of p70 S6 kinase-1 previously developed for the treatment of cancer. In two phase 1 trials in oncology patients, significant reductions of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride were observed. In the current study, we sought to understand the potential mechanism of action of this compound in regulating lipid metabolism. In Long Evans diet-induced obese (DIO) rats, oral administration of LY2584702 for 3-4 weeks led to robust reduction of LDL-C up to 60%. An unexpected finding of liver triglyceride (TG) increase implicated a metabolite of LY2584702, 4-aminopyrazolo[3,4-day]pyrimidine (4-APP), in modulation of lipid metabolism in these rats. We showed that low-dose 4-APP, when administered orally for 3-4 weeks to Long Evans DIO rats, produced lipoprotein profile changes that were strikingly similar to LY2584702. Kinetic studies suggested that both LY2584702 and 4-APP had no effect on chylomicron-TG secretion and only exerted a modest effect on hepatic very low-density lipoprotein (VLDL)-TG secretion. In human hepatoma HepG2 cells, 4-APP, but not LY2584702, increased LDL uptake. We hypothesize that generation of the 4-APP metabolite may contribute to the efficacy of LY2584702 in lowering LDL-C in rats and potentially in humans as well. This mechanism of LDL-C lowering may include inhibition of VLDL production and increase in LDL clearance.
Collapse
Affiliation(s)
- Thomas B Estridge
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Asim B Dey
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Charles Reidy
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Xiaohong Yu
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Yuke Zhang
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Maryalice Hartley
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Paul L Milligan
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Najia Jin
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Mark C Kowala
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Jennifer K Leohr
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Adrian J Fretland
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Thomas E Mabry
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - Debra Luffer-Atlas
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| | - M Jane Luo
- CardioMet Disease/Diabetic Complications (T.B.E., A.B.D., C.R., X.Y., Y.Z., N.J., M.H., M.C.K, M.J.L.), Discovery Chemistry and Research Technologies (P.L.M., T.E.M.), Global PK/PD & Pharmacometrics (J.K.L.), Drug Disposition (A.J.F., D.L.-A.), Eli Lilly & Co., Indianapolis, Indiana
| |
Collapse
|
8
|
Bisgaier CL, Ackermann R, Rea T, Rodrigueza WV, Hartman D. ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers. Pharmacol Res 2016; 111:86-99. [DOI: 10.1016/j.phrs.2016.05.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2015] [Revised: 05/02/2016] [Accepted: 05/02/2016] [Indexed: 12/15/2022]
|
9
|
Kim MH, de Beer MC, Wroblewski JM, Charnigo RJ, Ji A, Webb NR, de Beer FC, van der Westhuyzen DR. Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice. J Lipid Res 2016; 57:969-79. [PMID: 27018443 DOI: 10.1194/jlr.m062174] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Indexed: 01/12/2023] Open
Abstract
The acute phase (AP) reactant serum amyloid A (SAA), an HDL apolipoprotein, exhibits pro-inflammatory activities, but its physiological function(s) are poorly understood. Functional differences between SAA1.1 and SAA2.1, the two major SAA isoforms, are unclear. Mice deficient in either isoform were used to investigate plasma isoform effects on HDL structure, composition, and apolipoprotein catabolism. Lack of either isoform did not affect the size of HDL, normally enlarged in the AP, and did not significantly change HDL composition. Plasma clearance rates of HDL apolipoproteins were determined using native HDL particles. The fractional clearance rates (FCRs) of apoA-I, apoA-II, and SAA were distinct, indicating that HDL is not cleared as intact particles. The FCRs of SAA1.1 and SAA2.1 in AP mice were similar, suggesting that the selective deposition of SAA1.1 in amyloid plaques is not associated with a difference in the rates of plasma clearance of the isoforms. Although the clearance rate of SAA was reduced in the absence of the HDL receptor, scavenger receptor class B type I (SR-BI), it remained significantly faster compared with that of apoA-I and apoA-II, indicating a relatively minor role of SR-BI in SAA's rapid clearance. These studies enhance our understanding of SAA metabolism and SAA's effects on AP-HDL composition and catabolism.
Collapse
Affiliation(s)
- Myung-Hee Kim
- Departments of Internal Medicine, University of Kentucky Medical Center, Lexington, KY 40536
| | - Maria C de Beer
- Physiology, University of Kentucky Medical Center, Lexington, KY 40536 Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington, KY 40536
| | - Joanne M Wroblewski
- Departments of Internal Medicine, University of Kentucky Medical Center, Lexington, KY 40536 Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington, KY 40536
| | - Richard J Charnigo
- Departments of Statistics and Biostatistics, University of Kentucky, Lexington, KY 40506
| | - Ailing Ji
- Departments of Internal Medicine, University of Kentucky Medical Center, Lexington, KY 40536 Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington, KY 40536
| | - Nancy R Webb
- Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington, KY 40536 Pharmacology and Nutritional Sciences, University of Kentucky Medical Center, Lexington, KY 40536
| | - Frederick C de Beer
- Departments of Internal Medicine, University of Kentucky Medical Center, Lexington, KY 40536 Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington, KY 40536
| | - Deneys R van der Westhuyzen
- Departments of Internal Medicine, University of Kentucky Medical Center, Lexington, KY 40536 Saha Cardiovascular Research Center, University of Kentucky Medical Center, Lexington, KY 40536 Molecular and Cellular Biochemistry, University of Kentucky Medical Center, Lexington, KY 40536
| |
Collapse
|
10
|
Osei M, Griffin JL, Koulman A. Hyphenating size-exclusion chromatography with electrospray mass spectrometry; using on-line liquid-liquid extraction to study the lipid composition of lipoprotein particles. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2015; 29:1969-1976. [PMID: 26443395 PMCID: PMC4973665 DOI: 10.1002/rcm.7301] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 08/04/2015] [Accepted: 08/05/2015] [Indexed: 06/05/2023]
Abstract
RATIONALE Lipoproteins belong to the most commonly measured clinical biochemical parameters. Lipidomics is an orthogonal approach and aims to profile the individual lipid molecules that jointly form the lipoprotein particles. However, in the first step of the extraction of lipid molecules from serum, an organic solvent is used leading to dissociation of the lipoproteins. Thus far it has been impossible to combine lipidomics and lipoprotein analysis in one analytical system. METHODS Human plasma was diluted in phosphate-buffered saline (PBS) and injected onto a Superose 6 PC 3.2 column with PBS as a mobile phase to separate lipoproteins. The eluent was led to a Syrris FLLEX module, which also received CHCl3 /MeOH (3:1). The two phases were mixed and subsequently separated using a Teflon membrane in an especially designed pressurized flow chamber. The organic phase was led to a standard electrospray source of an Orbitrap mass spectrometer. RESULTS Size-exclusion chromatography (SEC) has been commonly applied to separate lipoproteins and is considered a practical alternative to ultracentrifugation. Through the on-line liquid-liquid extraction method it becomes possible to obtained detailed mass spectra of lipids across different lipoprotein fractions. The extracted ion chromatograms of specific lipid signals showed their distribution against the size of lipoprotein particles. CONCLUSIONS The application of on-line liquid-liquid extraction allows for the continuous electrospray-based mass spectral analysis of SEC eluent, providing the detailed lipid composition of lipoprotein particles separated by size. This approach provides new possibilities for the study of the biochemistry of lipoproteins.
Collapse
Affiliation(s)
- Michael Osei
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn Road, Cambridge, CB1 9NL, UK
| | - Julian L Griffin
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn Road, Cambridge, CB1 9NL, UK
| | - Albert Koulman
- Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn Road, Cambridge, CB1 9NL, UK
| |
Collapse
|
11
|
Schroeder KM, Beyer TP, Hansen RJ, Han B, Pickard RT, Wroblewski VJ, Kowala MC, Eacho PI. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res 2015; 56:2124-32. [PMID: 26392590 DOI: 10.1194/jlr.m061903] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Indexed: 11/20/2022] Open
Abstract
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum. Comparing the epitope of LY with other clinically tested PCSK9 mAbs, it was noted that the LY epitope excludes the furin cleavage site in PCSK9, whereas other mAbs span this site. In vitro exposure of PCSK9 to furin resulted in degradation of PCSK9 bound to LY, whereas cleavage was blocked by other mAbs. These other mAbs caused a significant accumulation of serum PCSK9 and displayed a shorter duration of LDL-cholesterol lowering than LY when administered to mice expressing the WT human PCSK9. In mice expressing a noncleavable variant of human PCSK9, LY behaved like a cleavage-blocking mAb, in that it caused significant PCSK9 accumulation, its duration of LDL lowering was reduced, and its clearance (CL) from serum was accelerated. Thus, LY neutralizes PCSK9 and allows its proteolytic degradation to proceed, which limits PCSK9 accumulation, reduces the CL rate of LY, and extends its duration of action. PCSK9 mAbs with this property are likely to achieve longer durability and require lower doses than mAbs that cause antigen to accumulate.
Collapse
Affiliation(s)
- Krista M Schroeder
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | - Thomas P Beyer
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | - Ryan J Hansen
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | - Bomie Han
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | - Richard T Pickard
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | | | - Mark C Kowala
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| | - Patrick I Eacho
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285
| |
Collapse
|
12
|
Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs. PLoS One 2015; 10:e0136934. [PMID: 26366727 PMCID: PMC4569091 DOI: 10.1371/journal.pone.0136934] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 08/10/2015] [Indexed: 11/19/2022] Open
Abstract
AIM Nicotinic acid (NA) treatment decreases plasma triglycerides and increases HDL cholesterol, but the mechanisms involved in these change are not fully understood. A reduction in cholesteryl ester transfer protein (CETP) activity has been advanced to explain most lipid-modulating effects of NA. However, due to the central role of CETP in reverse cholesterol transport in humans, other effects of NA may have been hidden. As dogs have no CETP activity, we conducted this study to examine the specific effects of extended-release niacin (NA) on lipids and high-density lipoprotein (HDL) cholesteryl ester (CE) turnover in obese Insulin-Resistant dogs with increase plasma triglycerides. METHODS HDL kinetics were assessed in fasting dogs before and four weeks after NA treatment through endogenous labeling of cholesterol and apolipoprotein AI by simultaneous infusion of [1,2 13C2] acetate and [5,5,5 2H3] leucine for 8 h. Kinetic data were analyzed by compartmental modeling. In vitro cell cholesterol efflux of serum from NA-treated dogs was also measured. RESULTS NA reduced plasma total cholesterol, low-density lipoprotein cholesterol, HDL cholesterol, triglycerides (TG), and very-low-density lipoprotein TG concentrations (p < 0.05). The kinetic study also showed a higher cholesterol esterification rate (p < 0.05). HDL-CE turnover was accelerated (p < 0.05) via HDL removal through endocytosis and selective CE uptake (p < 0.05). We measured an elevated in vitro cell cholesterol efflux (p < 0.05) with NA treatment in accordance with a higher cholesterol esterification. CONCLUSION NA decreased HDL cholesterol but promoted cholesterol efflux and esterification, leading to improved reverse cholesterol transport. These results highlight the CETP-independent effects of NA in changes of plasma lipid profile.
Collapse
|
13
|
Luz JG, Carson MW, Condon B, Clawson D, Pustilnik A, Kohlman DT, Barr RJ, Bean JS, Dill MJ, Sindelar DK, Maletic M, Coghlan MJ. Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site. J Med Chem 2015. [PMID: 26218343 DOI: 10.1021/acs.jmedchem.5b00736] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To further elucidate the structural activity correlation of glucocorticoid receptor (GR) antagonism, the crystal structure of the GR ligand-binding domain (GR LBD) complex with a nonsteroidal antagonist, compound 8, was determined. This novel indole sulfonamide shows in vitro activity comparable to known GR antagonists such as mifepristone, and notably, this molecule lowers LDL (-74%) and raises HDL (+73%) in a hamster model of dyslipidemia. This is the first reported crystal structure of the GR LBD bound to a nonsteroidal antagonist, and this article provides additional elements for the design and pharmacology of clinically relevant nonsteroidal GR antagonists that may have greater selectivity and fewer side effects than their steroidal counterparts.
Collapse
Affiliation(s)
- John G Luz
- Eli Lilly Biotechnology Center , 10300 Campus Point Drive, Suite 200, San Diego, California 92121 United States
| | - Matthew W Carson
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - Bradley Condon
- Eli Lilly Biotechnology Center , 10300 Campus Point Drive, Suite 200, San Diego, California 92121 United States
| | - David Clawson
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - Anna Pustilnik
- Eli Lilly Biotechnology Center , 10300 Campus Point Drive, Suite 200, San Diego, California 92121 United States
| | - Daniel T Kohlman
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - Robert J Barr
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - James S Bean
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - M Joelle Dill
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - Dana K Sindelar
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| | - Milan Maletic
- Eli Lilly Biotechnology Center , 10300 Campus Point Drive, Suite 200, San Diego, California 92121 United States
| | - Michael J Coghlan
- Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States
| |
Collapse
|
14
|
McConathy WJ, Paranjape S, Mooberry L, Buttreddy S, Nair M, Lacko AG. Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv Transl Res 2015; 1:113-20. [PMID: 25788110 DOI: 10.1007/s13346-010-0012-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Dilauryl fluorescein (DLF) is a lipid soluble molecule that becomes fluorescent when lauric acid is removed by hydrolysis The purpose of these studies was to evaluate DLF as a potential probe for the function of reconstituted high-density lipoproteins (rHDL) as hydrophobic drug transport vehicles. The DLF containing rHDL nanoparticles were characterized regarding their physical/chemical properties, including molecular diameter, molecular weight, chemical composition, and buoyant density. We investigated the uptake of DLF from rHDL in cells that overexpress the scavenger receptor (SR-B1), known to facilitate the selective cellular uptake of cholesteryl esters from HDL. These studies show that DLF can be incorporated into rHDL and redistributed in the plasma compartment. In addition, these studies demonstrated an enhanced uptake and hydrolysis of DLF from rHDL by cells that overexpress the SR-B1 receptor, suggesting the involvement of a receptor mediated mechanism. The incorporation of DLF into the rHDL nanoparticles appear to protect against hydrolysis in the systemic circulation based on the lower rate of rHDL/DLF hydrolysis compared with the free DLF during incubation with human plasma. DLF may thus be used as a probe to track the movement and metabolism of HDL core constituents, including cancer chemotherapeutic agents.
Collapse
Affiliation(s)
- Walter J McConathy
- Center for Diabetes and Metabolic Disorders, Department of Internal Medicine, Texas Tech University Health Sciences Center-Permian Basin, Odessa, TX, 79763, USA
| | | | | | | | | | | |
Collapse
|
15
|
Shelton KA, Cline JM, Cann JA. 17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice. Atherosclerosis 2013; 227:228-35. [PMID: 23395521 DOI: 10.1016/j.atherosclerosis.2012.12.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Revised: 12/17/2012] [Accepted: 12/17/2012] [Indexed: 11/18/2022]
Abstract
OBJECTIVE To test the hypothesis that estrogen treatment in a radiation chimera mouse model of systemic lupus erythematosus (SLE) and atherosclerosis will increase SLE-associated atherosclerosis by increasing autoantibody production and inflammation. METHODS We used a radiation chimera mouse model in which bone marrow from the polygenic B6.Sle1.2.3 model of SLE was transferred to the low density lipoprotein receptor knock out (LDLr(-/-)) model of atherosclerosis on a C57BL/6 background (Sle/LDLr(-/-)). Ovariectomized chimeric mice were treated for 10 weeks with either 5.6 μg/day of 17β-estradiol or placebo; outcomes included atherosclerosis plaque size, anti-dsDNA autoantibody production and renal pathology. RESULTS Mean atherosclerosis plaque size was 67.4 ± 7.6% smaller in the estrogen treated group (p < 0.0001). Estrogen treated Sle/LDLr(-/-) mice had no significant difference in serum cholesterol concentration, lipoprotein distribution, anti-dsDNA autoantibody concentration, antibody isotype concentration and renal histopathology score compared to placebo. However, they had significantly lower mean urine protein to urine creatinine ratio (UP:UC). There was no correlation between atherosclerosis lesion size and either the renal histology score or UP:UC ratio in Sle/LDLr(-/-) mice. CONCLUSION These results indicate that 17β-estradiol is atheroprotective within the context of murine SLE independent of changes in serum cholesterol concentration, autoantibody concentration, or renal pathology. The SLE phenotype in Sle/LDLr(-/-) mice is not exacerbated by exogenous 17β-estradiol administration, and the reduced UP:UC ratio suggests a protective effect against lupus nephritis.
Collapse
Affiliation(s)
- K A Shelton
- Department of Pathology, Section on Comparative Medicine, Medical Center Blvd., Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
| | | | | |
Collapse
|
16
|
Hypopigmentation and maternal-zygotic embryonic lethality caused by a hypomorphic mbtps1 mutation in mice. G3-GENES GENOMES GENETICS 2012; 2:499-504. [PMID: 22540041 PMCID: PMC3337478 DOI: 10.1534/g3.112.002196] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/27/2011] [Accepted: 02/15/2012] [Indexed: 12/28/2022]
Abstract
The site 1 protease, encoded by Mbtps1, mediates the initial cleavage of site 2 protease substrates, including sterol regulatory element binding proteins and CREB/ATF transcription factors. We demonstrate that a hypomorphic mutation of Mbtps1 called woodrat (wrt) caused hypocholesterolemia, as well as progressive hypopigmentation of the coat, that appears to be mechanistically unrelated. Hypopigmentation was rescued by transgenic expression of wild-type Mbtps1, and reciprocal grafting studies showed that normal pigmentation depended upon both cell-intrinsic or paracrine factors, as well as factors that act systemically, both of which are lacking in wrt homozygotes. Mbtps1 exhibited a maternal-zygotic effect characterized by fully penetrant embryonic lethality of maternal-zygotic wrt mutant offspring and partial embryonic lethality (~40%) of zygotic wrt mutant offspring. Mbtps1 is one of two maternal-zygotic effect genes identified in mammals to date. It functions nonredundantly in pigmentation and embryogenesis.
Collapse
|
17
|
Owens AP, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122:558-68. [PMID: 22214850 DOI: 10.1172/jci58969] [Citation(s) in RCA: 135] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2011] [Accepted: 11/09/2011] [Indexed: 11/17/2022] Open
Abstract
Hypercholesterolemia is a major risk factor for atherosclerosis. It also is associated with platelet hyperactivity, which increases morbidity and mortality from cardiovascular disease. However, the mechanisms by which hypercholesterolemia produces a procoagulant state remain undefined. Atherosclerosis is associated with accumulation of oxidized lipoproteins within atherosclerotic lesions. Small quantities of oxidized lipoproteins are also present in the circulation of patients with coronary artery disease. We therefore hypothesized that hypercholesterolemia leads to elevated levels of oxidized LDL (oxLDL) in plasma and that this induces expression of the procoagulant protein tissue factor (TF) in monocytes. In support of this hypothesis, we report here that oxLDL induced TF expression in human monocytic cells and monocytes. In addition, patients with familial hypercholesterolemia had elevated levels of plasma microparticle (MP) TF activity. Furthermore, a high-fat diet induced a time-dependent increase in plasma MP TF activity and activation of coagulation in both LDL receptor-deficient mice and African green monkeys. Genetic deficiency of TF in bone marrow cells reduced coagulation in hypercholesterolemic mice, consistent with a major role for monocyte-derived TF in the activation of coagulation. Similarly, a deficiency of either TLR4 or TLR6 reduced levels of MP TF activity. Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte TF expression, MP TF activity, activation of coagulation, and inflammation, without affecting total cholesterol levels. Our results suggest that the prothrombotic state associated with hypercholesterolemia is caused by oxLDL-mediated induction of TF expression in monocytes via engagement of a TLR4/TLR6 complex.
Collapse
Affiliation(s)
- A Phillip Owens
- Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Nguyen TM, Sawyer JK, Kelley KL, Davis MA, Rudel LL. Cholesterol esterification by ACAT2 is essential for efficient intestinal cholesterol absorption: evidence from thoracic lymph duct cannulation. J Lipid Res 2012; 53:95-104. [PMID: 22045928 PMCID: PMC3243485 DOI: 10.1194/jlr.m018820] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Revised: 10/11/2011] [Indexed: 01/21/2023] Open
Abstract
The hypothesis tested in this study was that cholesterol esterification by ACAT2 would increase cholesterol absorption efficiency by providing cholesteryl ester (CE) for incorporation into chylomicrons. The assumption was that absorption would be proportional to Acat2 gene dosage. Male ACAT2⁺/⁺, ACAT2⁺/⁻, and ACAT2⁻/⁻ mice were fed a diet containing 20% of energy as palm oil with 0.2% (w/w) cholesterol. Cholesterol absorption efficiency was measured by fecal dual-isotope and thoracic lymph duct cannulation (TLDC) methods using [³H]sitosterol and [¹⁴C]cholesterol tracers. Excellent agreement among individual mice was found for cholesterol absorption measured by both techniques. Cholesterol absorption efficiency in ACAT2⁻/⁻ mice was 16% compared with 46-47% in ACAT2⁺/⁺ and ACAT2⁺/⁻ mice. Chylomicrons from ACAT2⁺/⁺ and ACAT2⁺/⁻ mice carried ∼80% of total sterol mass as CE, whereas ACAT2⁻/⁻ chylomicrons carried >90% of sterol mass in the unesterified form. The total percentage of chylomicron mass as CE was reduced from 12% in the presence of ACAT2 to ∼1% in ACAT2⁻/⁻ mice. Altogether, the data demonstrate that ACAT2 increases cholesterol absorption efficiency by providing CE for chylomicron transport, but one copy of the Acat2 gene, providing ∼50% of ACAT2 mRNA and enzyme activity, was as effective as two copies in promoting cholesterol absorption.
Collapse
Affiliation(s)
| | - Janet K. Sawyer
- Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC
| | - Kathryn L. Kelley
- Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC
| | - Matthew A. Davis
- Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC
| | - Lawrence L. Rudel
- Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC
| |
Collapse
|
19
|
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478:404-7. [PMID: 22012398 PMCID: PMC3235584 DOI: 10.1038/nature10486] [Citation(s) in RCA: 572] [Impact Index Per Article: 44.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2011] [Accepted: 08/17/2011] [Indexed: 02/06/2023]
Abstract
Cardiovascular disease (CVD) remains the leading cause of mortality in westernized countries, despite optimum medical therapy to lower LDL cholesterol. The pursuit of novel therapies to target this residual risk has focused on raising levels of HDL cholesterol in order to exploit its atheroprotective effects1. MicroRNAs have emerged as important post-transcriptional regulators of lipid metabolism, and are thus a new class of targets for therapeutic intervention2. MicroRNA-33a and b (miR-33a/b) are intronic microRNAs embedded in the sterol response element binding protein genes SREBF2 and SREBF13–5, respectively, that repress expression of the cholesterol transporter ABCA1, a key regulator of HDL biogenesis. Recent studies in mice suggest that antagonizing miR-33a may be an effective strategy for raising plasma HDL3–5 and protecting from atherosclerosis6, however extrapolation of these findings to humans is complicated by the fact that mice lack miR-33b which is present only in the SREBF1 gene of higher mammals. Here we show in African green monkeys that systemic delivery of an anti-miR oligonucleotide that targets both miR-33a and miR-33b increases hepatic expression of ABCA1 and induces a sustained increase in plasma HDL over 12 weeks. Notably, miR-33 antagonism in this non-human primate model also increased the expression of miR-33 target genes involved in the oxidation of fatty acids (CROT, CPT1A, HADHB, PRKAA1) and reduced genes involved in fatty acid synthesis (SREBF1, FASN, ACLY, ACACA), resulting in a marked suppression of plasma VLDL triglyceride levels, a finding not previously observed in mice. These data establish, in a model highly relevant to humans, that pharmacological inhibition of miR-33a and b is a promising therapeutic strategy to raise plasma HDL and lower VLDL triglycerides for the treatment of dyslipidemias that increase cardiovascular disease risk.
Collapse
|
20
|
Previs SF, Mahsut A, Kulick A, Dunn K, Andrews-Kelly G, Johnson C, Bhat G, Herath K, Miller PL, Wang SP, Azer K, Xu J, Johns DG, Hubbard BK, Roddy TP. Quantifying cholesterol synthesis in vivo using (2)H(2)O: enabling back-to-back studies in the same subject. J Lipid Res 2011; 52:1420-8. [PMID: 21498887 DOI: 10.1194/jlr.d014993] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The advantages of using (2)H(2)O to quantify cholesterol synthesis include i) homogeneous precursor labeling, ii) incorporation of (2)H via multiple pathways, and iii) the ability to perform long-term studies in free-living subjects. However, there are two concerns. First, the t(1/2) of tracer in body water presents a challenge when there is a need to acutely replicate measurements in the same subject. Second, assumptions are made regarding the number of hydrogens (n) that are incorporated during de novo synthesis. Our primary objective was to determine whether a step-based approach could be used to repeatedly study cholesterol synthesis a subject. We observed comparable changes in the (2)H-labeling of plasma water and total plasma cholesterol in African-Green monkeys that received five oral doses of (2)H(2)O, each dose separated by one week. Similar rates of cholesterol synthesis were estimated when comparing data in the group over the different weeks, but better reproducibility was observed when comparing replicate determinations of cholesterol synthesis in the same nonhuman primate during the respective dosing periods. Our secondary objective was to determine whether n depends on nutritional status in vivo; we observed n of ∼25 and ∼27 in mice fed a high-carbohydrate (HC) versus carbohydrate-free (CF) diet, respectively. We conclude that it is possible to acutely repeat studies of cholesterol synthesis using (2)H(2)O and that n is relatively constant.
Collapse
|
21
|
Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J. RVX-208. J Am Coll Cardiol 2010; 55:2580-9. [DOI: 10.1016/j.jacc.2010.02.035] [Citation(s) in RCA: 184] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2009] [Revised: 01/08/2010] [Accepted: 02/01/2010] [Indexed: 11/25/2022]
|
22
|
Stephens AM, Dean LL, Davis JP, Osborne JA, Sanders TH. Peanuts, Peanut Oil, and Fat Free Peanut Flour Reduced Cardiovascular Disease Risk Factors and the Development of Atherosclerosis in Syrian Golden Hamsters. J Food Sci 2010; 75:H116-22. [DOI: 10.1111/j.1750-3841.2010.01569.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Casimiro-Garcia A, Bigge CF, Davis JA, Padalino T, Pulaski J, Ohren JF, McConnell P, Kane CD, Royer LJ, Stevens KA, Auerbach B, Collard W, McGregor C, Song K. Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. Bioorg Med Chem 2009; 17:7113-25. [PMID: 19783444 DOI: 10.1016/j.bmc.2009.09.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2009] [Revised: 08/31/2009] [Accepted: 09/02/2009] [Indexed: 11/29/2022]
Abstract
The synthesis of a new series of phenylpropanoic acid derivatives incorporating an heteroaryl group at the alpha-position and their evaluation for binding and activation of PPARalpha and PPARgamma are presented in this report. Among the new compounds, (S)-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,3-triazol-2-yl-propionic acid (17j), was identified as a potent human PPARalpha/gamma dual agonist (EC(50)=0.013 and 0.061 microM, respectively) with demonstrated oral bioavailability in rat and dog. 17j was shown to decrease insulin levels, plasma glucose, and triglycerides in the ZDF female rat model. In the human apolipoprotein A-1/CETP transgenic mouse model 17j produced increases in hApoA1 and HDL-C and decreases in plasma triglycerides. The increased potency for binding and activation of both PPAR subtypes observed with 17j when compared to previous analogs in this series was explained based on results derived from crystallographic and modeling studies.
Collapse
Affiliation(s)
- Agustin Casimiro-Garcia
- Department of Chemistry, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Jericó MM, De Chiquito FC, Kajihara K, Antonio M, Moreira B, Gonzales R, Machado FLA, Nunes VS, Catanozi S, Nakandakare ER. Chromatographic Analysis of Lipid Fractions in Healthy Dogs and Dogs with Obesity or Hyperadrenocorticism. J Vet Diagn Invest 2009; 21:203-7. [DOI: 10.1177/104063870902100204] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Obesity and endogenous hyperadrenocorticism (HAC) are common clinical conditions in veterinary practice, and both conditions have clinical and laboratory similarities, such as weight gain and dyslipidemia. The objective of the present study was to characterize and compare the lipid profiles and plasma lipoprotein fractions in healthy dogs ( n = 10), in obese dogs ( n = 10), and in dogs with HAC ( n = 6). All of the dogs were client owned. The lipoproteins were separated by fast protein liquid chromatography, and the plasma concentrations of total cholesterol and total triacylglycerol (TAG) were determined by enzymatic methods. When compared with the healthy and obese groups, dogs with HAC had a significant increase ( P < 0.01) in the total concentrations of TAGs and cholesterol (CHOL), with higher distribution in the very low-density lipoprotein (VLDL)–CHOL fractions. In addition, the distributions of the high-density lipoprotein (HDL)–CHOL and HDL–TAG fractions were significantly lower ( P < 0.01) in dogs with HAC than in healthy dogs. Considering the animals in this study, it was determined that the dogs with HAC differed significantly from the healthy and obese dogs regarding the metabolism of CHOL and TAG, as well as their VLDL and HDL fractions. Similar laboratory findings could allow veterinarians to distinguish obese dogs from those with HAC. In addition, dogs with HAC may be at higher risk for developing metabolic and atherosclerotic complications.
Collapse
Affiliation(s)
| | | | - Kazuo Kajihara
- Anhembi Morumbi University, Veterinary Hospital, São Paulo, Brazil
| | | | | | - Rodrigo Gonzales
- Anhembi Morumbi University, Veterinary Hospital, São Paulo, Brazil
| | | | - Valéria Sutti Nunes
- the Lipids Laboratory (LIM 10) of the Faculty of Medicine, University of Sao Paulo, Brazil
| | - Sergio Catanozi
- the Lipids Laboratory (LIM 10) of the Faculty of Medicine, University of Sao Paulo, Brazil
| | | |
Collapse
|
25
|
Li L, Weng W, Harrison EH, Fisher EA. Plasma carboxyl ester lipase activity modulates apolipoprotein B-containing lipoprotein metabolism in a transgenic mouse model. Metabolism 2008; 57:1361-8. [PMID: 18803939 PMCID: PMC2587065 DOI: 10.1016/j.metabol.2008.05.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2007] [Accepted: 05/13/2008] [Indexed: 10/21/2022]
Abstract
Pancreatic carboxyl ester lipase (CEL) is in the plasma of many mammals, including humans and rats, but not mice. In vitro, CEL hydrolyzes cholesterol esters of apolipoprotein B-containing lipoproteins (apo B-Lp). To study the effect of CEL on metabolism of apo B-Lp and atherosclerosis in vivo, apo E-knockout (EKO) mice, which have high plasma levels of apo B-Lp and are prone to atherosclerosis, were made to secrete CEL into plasma by introducing a transgene containing a liver-specific promoter and rat CEL complementary DNA. Plasma CEL activity in EKO-CEL mice was comparable with that found in rats. Evidence of modification of apo B-Lp by plasma CEL in vivo was an increase in the free cholesterol to cholesterol ester ratio of apo B-Lp from mice on chow or a Western-type diet. In addition, plasma total cholesterol levels were elevated in EKO-CEL mice, with the elevation found exclusively in the apo B-Lp fraction. Associated with the increase in steady-state apo B-Lp levels was an increase in the plasma half-life of very low-density lipoproteins (VLDL) in EKO-CEL mice, measured by the clearance rate of injected VLDL. Interestingly, despite the increase of apo B-Lp, the atherosclerotic lesion did not differ between EKO and EKO-CEL mice on a Western-type diet. In summary, our results demonstrate that plasma CEL modulates apo B-Lp metabolism in vivo, resulting in reduced VLDL clearance and elevated plasma cholesterol levels.
Collapse
Affiliation(s)
- Ling Li
- Laboratory of Lipoprotein Research, Cardiovascular Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
| | | | | | | |
Collapse
|
26
|
Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun 2008; 370:634-40. [DOI: 10.1016/j.bbrc.2008.04.004] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2008] [Accepted: 04/02/2008] [Indexed: 10/22/2022]
|
27
|
An optimized fast-performance liquid chromatography method for analyzing lipoprotein profiles using microliter volumes of serum. Anal Biochem 2008; 376:268-74. [PMID: 18358227 DOI: 10.1016/j.ab.2008.02.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2008] [Revised: 02/26/2008] [Accepted: 02/27/2008] [Indexed: 11/20/2022]
Abstract
Plasma or serum lipoprotein analysis is commonly carried out with a conventional size-exclusion fast-performance liquid chromatography method that requires large sample volumes (1-2 ml). To determine lipoprotein profiles of mice with this method, plasma or serum samples have to be pooled from a group of animals, which often requires sacrificing animals. Here we report an optimized anion-exchange chromatography method with simplified cholesterol collection and detection system. After 5-10 microl serum was injected for anion-exchange chromatography, a stepwise gradient was applied and fractions were collected on a 96-well plate. Cholesterol content in each well was measured using a fluorescence-based detection method. With this method, distinct lipoprotein peaks corresponding to high-density lipoprotein, low-density lipoprotein, and very-low-density lipoprotein, can be easily separated and identified with excellent resolution. The entire high-performance liquid chromatography run takes about 30min and the results are reproducible with a low variability. The small sample size allows analyzing the lipoprotein profile in a given mouse at a given time point with nonterminal bleeding. The method is simple to set up with commercially available parts and convenient to run.
Collapse
|
28
|
Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008; 19:183-8. [DOI: 10.1097/cad.0b013e3282f1da86] [Citation(s) in RCA: 104] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
29
|
Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T. Development of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol. Clin Chem 2007; 53:2128-35. [PMID: 17901111 DOI: 10.1373/clinchem.2007.092296] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
AbstractBackground: Quantification of triglyceride-rich lipoprotein (TRL) remnants is useful for risk assessment of coronary artery disease and the diagnosis of type III hyperlipoproteinemia. Although an immunoseparation procedure for remnant-like particle cholesterol has been evaluated extensively in recent years, available methods for measuring TRL remnants have not achieved wide use in routine laboratory practice, suggesting a need for a homogeneous assay that can measure TRL remnant cholesterol in serum or plasma without pretreatment.Methods: We screened for suitable surfactants that exhibited favorable selectivity toward the VLDL remnant (VLDLR) fraction, including intermediate-density lipoproteins (IDLs). We investigated the principal characteristics of this assay by gel filtration of lipoproteins and their particle size distribution. We developed a simple assay and evaluated its performance with the Hitachi-7170 analyzer.Results: Polyoxyethylene-polyoxybutylene block copolymer (POE-POB) exhibited favorable selectivity toward VLDLR and IDL fractions. POE-POB removed apolipoprotein (apo) E and apo C-III from IDL particles in the presence of cholesterol esterase (CHER), and the particle size distribution of IDLs became smaller after the reaction. These results revealed that IDL particles are specifically modified in the presence of CHER and POE-POB, making their component cholesterol available for enzymatic assay. Addition of phospholipase D improved the reactivity toward chylomicron remnants (CMRs). We found a high correlation [y = 1.018x− 0.01 mmol/L, r = 0.962 (n = 160)] between the proposed assay and the immunoseparation assay in serum from healthy individuals.Conclusion: The homogeneous assay described in this report can measure TRL remnant cholesterol, including CMRs, VLDLRs, and IDLs, with high sensitivity and specificity.
Collapse
Affiliation(s)
- Kazuhito Miyauchi
- Scientific and Technical Affairs Department, Kyowa Medex Co., Ltd., Tokyo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Sato K, Ohuchi A, Sato T, Schneider WJ, Akiba Y. Molecular characterization and expression of the cholesteryl ester transfer protein gene in chickens. Comp Biochem Physiol B Biochem Mol Biol 2007; 148:117-23. [PMID: 17574888 DOI: 10.1016/j.cbpb.2007.05.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2007] [Revised: 05/02/2007] [Accepted: 05/02/2007] [Indexed: 11/17/2022]
Abstract
The cDNA for cholesteryl ester transfer protein (CETP), a protein that catalyzes cholesteryl ester transfer between very low density and high density lipoproteins in plasma, was isolated from chicken liver. When the recombinant protein was overexpressed in HEK293 cells, cholesteryl ester transfer activity was observed in media and cell lysates. By Northern blot analysis, chicken CETP mRNA expression was detected in liver, brain, heart, and spleen. Changes in chicken CETP mRNA expression and plasma CETP activity with nutritional state were examined and found to increase following dietary supplementation with cholesterol in a similar way as in humans. Both the hepatic CETP mRNA levels and plasma CETP activity were significantly lower in mature (i.e egg-laying) hens than in immature female chickens, but were unaffected by age in male animals. Similar changes to those observed in female chickens were observed upon estradiol administration of males. The present study is the first to report the molecular characterization of an avian CETP, and the impairments of CETP gene and activity, which might be regulated by estrogen, play an important role in egg production in laying hens, demonstrating species-specific differences in the lipid metabolism of avian and mammalian species.
Collapse
Affiliation(s)
- Kan Sato
- Animal Science, Applied Bioproduction Science, Biological Production, Tokyo University of Agriculture and Technology, 183-8509, Japan.
| | | | | | | | | |
Collapse
|
31
|
Navarro V, Macarulla MT, Fernández-Quintela A, Rodríguez VM, Simón E, Portillo MP. Effects of trans-10,cis-12 conjugated linoleic acid on cholesterol metabolism in hypercholesterolaemic hamsters. Eur J Nutr 2007; 46:213-9. [PMID: 17479210 DOI: 10.1007/s00394-007-0653-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2006] [Accepted: 03/22/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND Conjugated linoleic acid (CLA) has received great attention in recent years because of its pleiotropic biological activities, but considerably fewer studies have been published addressing its role in serum lipids and atherosclerosis compared to other topics covered. AIMS OF THE STUDY The aim of the present study was to assess the effects of the trans-10,cis-12 isomer of CLA on cholesterolaemia and on several metabolic pathways involved in cholesterol metabolism in hamsters. METHODS Animals were fed atherogenic diets supplemented with 0.5% linoleic acid, 0.5% trans-10,cis-12 CLA or 1.0% trans-10,cis-12 CLA, for 6 weeks. Serum lipoproteins were separated by FPLC. Cholesterol in serum and liver, as well as triacylglycerols and phospholipids in liver were assessed by spectrophotometry. 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR), acyl-coenzyme A:cholesterol acyltransferase (ACAT) and cholesteryl ester hydrolase (CEH) activities were measured by radiometry, and LDL receptors were determined by Western blot. RESULTS trans-10,cis-12 CLA feeding did not modify food intake nor final body weight. Although serum total cholesterol remained unchanged, when cholesterol fractions were analyzed a significant decrease in VLDL-cholesterol was observed in CLA-fed animals, without changes in HDL-cholesterol or LDL-cholesterol. trans-10,cis-12 CLA decreased cholesterol ester content and increased free cholesterol in liver. The activity of HMGCoAR was not modified. In contrast, ACAT activity was reduced by both CLA doses and CEH was increased by the high CLA dose. LDL receptors were significantly reduced by trans-10,cis-12 feeding when expressed as arbitrary units per mg of protein, however, the total receptor mass remained unchanged. CONCLUSIONS These results suggest that, under the present experimental conditions, trans-10,cis-12 CLA feeding reduces cholesterol esterification in liver and decreases the minority serum VLDL-cholesterol fraction, but it does not show a hypocholesterolaemic effect. A dose-response effect was not observed.
Collapse
Affiliation(s)
- Virginia Navarro
- Dept. of Nutrition and Food Science, Faculty of Pharmacy, University of País Vasco, Paseo de la Universidad 7, 01006 Vitoria, Spain
| | | | | | | | | | | |
Collapse
|
32
|
Degrace P, Moindrot B, Mohamed I, Gresti J, Clouet P. Moderate consumption of beer reduces liver triglycerides and aortic cholesterol deposit in LDLr−/− apoB100/100 mice. Atherosclerosis 2006; 189:328-35. [PMID: 16487531 DOI: 10.1016/j.atherosclerosis.2006.01.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2005] [Revised: 01/11/2006] [Accepted: 01/16/2006] [Indexed: 10/25/2022]
Abstract
This study was designed to address the effects of a moderate consumption of beer on serum and liver lipid parameters and on the development of aortic lesions in a mouse model associated with a human atherogenic lipoprotein profile. LDLr(-/-) apoB(100/100) mice received each day during 12 weeks either water, mild beer (0.570g of ethanol/kg of body weight) or ethanol-free beer in a single pure dose. Serum and liver lipid parameters were analyzed and atherosclerotic lesions were estimated in heart and aorta through their total cholesterol content. mRNA levels of enzymes and receptors involved in lipoprotein uptake, in fatty acid esterification and oxidation, and in reverse cholesterol transport were also measured in the liver. Serum glucose, triglyceride (TG) and cholesterol levels were altered neither by ethanol-free beer nor by mild beer. Nevertheless, both beer treatments significantly increased HDL-cholesterol (HDL-C) and VLDL-C levels by reference to controls with no change in LDL-C levels. Liver TG contents were significantly decreased by either beer treatment. Cholesterol accumulation was attenuated in the whole aorta of mice treated with mild beer at p<0.05 and not significantly with ethanol-free beer. Heart cholesterol contents were comparable in the three series. Among the genes studied, only scavenger receptor-B1 was downregulated by both beer-based beverages. LDL receptor related protein, lecithin-cholesterol acyltransferase and sterol regulatory element-binding protein 2 were downregulated only by mild beer. The expression of other genes assayed was not altered. When administered in chronic and moderate dose, unidentified components of beer may exert beneficial effects towards atherosclerosis development through alteration of lipoprotein metabolism in LDLr(-/-) apoB(100/100) mice. This effect was slightly amplified by the presence of ethanol in beer.
Collapse
MESH Headings
- Alcohol Drinking
- Animals
- Aorta, Thoracic/metabolism
- Aortic Diseases/metabolism
- Aortic Diseases/prevention & control
- Apolipoproteins B/deficiency
- Atherosclerosis/metabolism
- Atherosclerosis/prevention & control
- Beer
- Cholesterol, HDL/metabolism
- Cholesterol, LDL/metabolism
- Cholesterol, VLDL/metabolism
- Chromatography, High Pressure Liquid
- Down-Regulation
- Female
- Liver/metabolism
- Mice
- Mice, Inbred C57BL
- Mitochondria, Liver/metabolism
- Oxidation-Reduction
- Palmitates/metabolism
- Phosphatidylcholine-Sterol O-Acyltransferase/genetics
- Polymerase Chain Reaction
- RNA, Messenger/genetics
- Receptors, LDL/deficiency
- Receptors, LDL/genetics
- Scavenger Receptors, Class B/genetics
- Sterol Regulatory Element Binding Protein 2/genetics
- Triglycerides/metabolism
Collapse
Affiliation(s)
- Pascal Degrace
- UPRES Lipides et Nutrition EA2422, Faculté des Sciences Gabriel, Université de Bourgogne, 6 Bd Gabriel, 21000 Dijon, France.
| | | | | | | | | |
Collapse
|
33
|
Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 2006; 26:6786-98. [PMID: 16943421 PMCID: PMC1592860 DOI: 10.1128/mcb.00077-06] [Citation(s) in RCA: 176] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Stearoyl-coenzyme A desaturase (SCD) is the rate-limiting enzyme necessary for the biosynthesis of monounsaturated fatty acids. In this study, we investigated the regulation of mouse SCD1 by liver X receptor (LXR) and its role in plasma lipoprotein metabolism upon LXR activation. In vivo, the SCD1 gene remained induced upon LXR activation in the absence of sterol regulatory element-binding protein 1c (SREBP-1c), a known transcriptional regulator of SCD1. Serial deletion and point mutation analyses in reporter gene assays, as well as a gel mobility shift assay, identified an LXR response element in the mouse SCD1 promoter. In addition, SCD1 deficiency prevented the hypertriglyceridemic effect and reduced hepatic triglyceride accumulation associated with LXR activation despite induced hepatic expression of SREBP-1c protein and several SREBP1c and LXR target genes involved in lipoprotein metabolism. Unlike wild-type mice, SCD1-deficient mice failed to elevate the hepatic triglyceride monounsaturated acid (MUFA)/saturated fatty acid (SFA) ratio despite induction of the SCD2 gene. Together, these findings suggest that SCD1 plays a pivotal role in the regulation of hepatic and plasma triglyceride accumulation, possibly by modulating the MUFA-to-SFA ratio. In addition, SCD1 deficiency also increased plasma high-density lipoprotein cholesterol levels induced by LXR activation.
Collapse
Affiliation(s)
- Kiki Chu
- Department of Biochemistry, University of Wisconsin-Madison, 433 Babcock Drive, Madison, WI 53706, USA
| | | | | | | |
Collapse
|
34
|
Porsgaard T, Xu X, Mu H. The form of dietary conjugated linoleic acid does not influence plasma and liver triacylglycerol concentrations in Syrian golden hamsters. J Nutr 2006; 136:2201-6. [PMID: 16857841 DOI: 10.1093/jn/136.8.2201] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Several studies have shown that conjugated linoleic acid (CLA) supplementation can improve the plasma lipid profile and thereby probably decrease the risk for development of atherosclerosis. The aim of the present study was to compare the effects on plasma and organ lipids of different dietary forms of CLA: triacylglycerol (TAG), diacylglycerol (DAG), monoacylglycerol (MAG), and fatty acid ethyl esters (FAEEs). DAG-, MAG-, and FAEE-CLA were produced by enzymatic interesterifications and all supplements were composed of a 1:1 mixture of the 2 major CLA isomers: cis-9, trans-11 and trans-10, cis-12. Male Syrian Golden hamsters were fed mildly atherogenic diets (10 g butter/100 g, 0.1 g cholesterol/100 g) supplemented with 0.5 g CLA/100 g or without CLA (control) for 8 wk. Liver weights were greater in the TAG- and FAEE-CLA groups than in the control group. In general, the form of CLA did not differentially affect plasma or liver cholesterol or plasma lipoprotein cholesterol concentrations, but only the TAG-CLA group had a higher final plasma TAG concentration than the control group. Both CLA isomers were incorporated into plasma, livers, and spleens. The results of the present study suggest that the form in which CLA is supplemented in the diet does not affect hamster plasma and liver TAG concentrations. The TAG-CLA form, a frequently used form of supplemental CLA, increases plasma TAG concentrations. If similar effects occur in humans, supplemental TAG-CLA cannot be considered to be beneficial given the relation between plasma TAG and the development of atherosclerosis.
Collapse
Affiliation(s)
- Trine Porsgaard
- Biochemistry and Nutrition Group, BioCentrum-DTU, Technical University of Denmark, 2800 Lyngby, Denmark
| | | | | |
Collapse
|
35
|
Alberts P, Klingström G, Arrhenius‐Nyberg V, Larsson C, Sakariassen KS. A micro‐method for lipoprotein cholesterol profiles: Impact of CETP in KKA
y
mice. EUR J LIPID SCI TECH 2006. [DOI: 10.1002/ejlt.200500261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Pe¯teris Alberts
- Pharmacology, Department of Biology, Biovitrum, Stockholm, Sweden
| | | | | | - Catarina Larsson
- Pharmacology, Department of Biology, Biovitrum, Stockholm, Sweden
| | - Kjell S. Sakariassen
- Pharmacology, Department of Biology, Biovitrum, Stockholm, Sweden
- Present address: KellSa s.a.s., Str. Campo e Zampe 12, I‐13900 Biella, BI, Italy
| |
Collapse
|
36
|
Park TS, Panek RL, Rekhter MD, Mueller SB, Rosebury WS, Robertson A, Hanselman JC, Kindt E, Homan R, Karathanasis SK. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006; 189:264-72. [PMID: 16458317 DOI: 10.1016/j.atherosclerosis.2005.12.029] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2005] [Revised: 12/14/2005] [Accepted: 12/19/2005] [Indexed: 11/16/2022]
Abstract
Plasma sphingomyelin (SM) has been suggested as a risk factor for coronary heart disease independent of cholesterol levels. A decrease of SM in lipoproteins is known to improve the activities of lecithin:cholesterol acyltransferase (LCAT) and lipoprotein lipase (LPL) in vitro. Inhibition of SM biosynthesis may reduce lipoprotein SM content and thus improve cholesterol distribution in lipoproteins by enhancing reverse cholesterol transport and clearance of triglyceride-rich lipoproteins. To examine this hypothesis, ApoE KO mice were fed a western diet and treated for 4 weeks with various concentrations of myriocin, a specific inhibitor of serine palmitoyltransferase. Myriocin treatment lowered plasma cholesterol and TG levels in a dose-dependent manner. In addition, myriocin treatment reduced cholesterol contents in VLDL and LDL and elevated HDL-cholesterol. Observed lipid-lowering effects of myriocin were associated with suppression of HMG CoA reductase and fatty acid synthase via reduced levels of SREBP-1 RNA and protein. Induction of apoAI and lecithin:cholesterol acytransferase (LCAT) in the liver by myriocin was associated with an increased HDL. Lesion area and macrophage area were also diminished in the cuffed femoral artery of ApoE KO mice. In conclusion, inhibition of sphingolipid biosynthesis can be a novel therapeutic target for dyslipidemia and atherosclerosis.
Collapse
Affiliation(s)
- Tae-Sik Park
- Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3:87-98. [PMID: 16459310 DOI: 10.1016/j.cmet.2006.01.005] [Citation(s) in RCA: 1595] [Impact Index Per Article: 88.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2005] [Revised: 01/04/2006] [Accepted: 01/10/2006] [Indexed: 02/07/2023]
Abstract
Current understanding of microRNA (miRNA) biology is limited, and antisense oligonucleotide (ASO) inhibition of miRNAs is a powerful technique for their functionalization. To uncover the role of the liver-specific miR-122 in the adult liver, we inhibited it in mice with a 2'-O-methoxyethyl phosphorothioate ASO. miR-122 inhibition in normal mice resulted in reduced plasma cholesterol levels, increased hepatic fatty-acid oxidation, and a decrease in hepatic fatty-acid and cholesterol synthesis rates. Activation of the central metabolic sensor AMPK was also increased. miR-122 inhibition in a diet-induced obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis, accompanied by reductions in several lipogenic genes. These results implicate miR-122 as a key regulator of cholesterol and fatty-acid metabolism in the adult liver and suggest that miR-122 may be an attractive therapeutic target for metabolic disease.
Collapse
Affiliation(s)
- Christine Esau
- Isis Pharmaceuticals, 1896 Rutherford Road, Carlsbad, California 92008, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Parini P, Johansson L, Bröijersén A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 2006; 36:98-104. [PMID: 16436091 DOI: 10.1111/j.1365-2362.2006.01597.x] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND High-quality methods for lipoprotein characterization are warranted in studies on various metabolic diseases. MATERIALS AND METHODS An automated system for size-exclusion chromatography (SEC) of lipoproteins using commercially available components is described. Cholesterol or triglyceride content in separated lipoproteins from plasma and interstitial fluid (IF) was continuously determined on-line using microlitre sample volumes. RESULTS The lipoprotein assay showed a good concordance with the classic ultra-centrifugation/precipitation technique using fresh or frozen samples. Determination of lipoproteins in IF obtained from vacuum-induced skin blisters from 18 healthy subjects revealed that very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol levels were 18%, 19% and 25%, respectively, of concomitant plasma concentrations. The size-exclusion chromatography (SEC) system also allows for triglyceride determination on-line and it could be shown that the system is advantageous for an accurate determination of triglycerides in conditions when there are high levels of glycerol, e.g. in mice and in patients with hyperglycerolaemia (pseudo-hypertriglyceridaemia). CONCLUSIONS The described system should be of value in studies where detailed lipoprotein analysis is warranted and particularly when significant sample series with small volumes are available. Our data also suggest that there is a 4-5.5-fold concentration gradient between plasma and IF for the three major plasma lipoproteins.
Collapse
Affiliation(s)
- P Parini
- Center for Nutrition and Toxicology, Karolinska Institute at Karolinska University Hospital, Stockholm, Sweden
| | | | | | | | | |
Collapse
|
39
|
Oniciu DC, Dasseux JLH, Yang J, Mueller R, Pop E, Denysenko A, Duan C, Huang TB, Zhang L, Krause BR, Drake SL, Lalwani N, Cramer CT, Goetz B, Pape ME, McKee A, Fici GJ, Lutostanski JM, Brown SC, Bisgaier CL. Influence of Various Central Moieties on the Hypolipidemic Properties of Long Hydrocarbon Chain Diols and Diacids. J Med Chem 2005; 49:334-48. [PMID: 16392818 DOI: 10.1021/jm050650j] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A series of long (11-15) hydrocarbon chain diols and diacids with various central functional groups and terminal gem-dimethyl or -methyl/aryl substituents was synthesized and evaluated in both in vivo and in vitro assays for its potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes, as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats, Crl:(ZUC)-faBR. The most active compounds were hydroxyl-substituted symmetrical diacids and diols with a 13-atom chain and terminal gem-dimethyl substituents. Furthermore, biological activity was enhanced by central substitution with O, C=O, S, S=O compared to the methylene analogues and was diminished for compounds with central functional groups such as carbamate, ester, urea, acetylmethylene, and hydroxymethylene.
Collapse
Affiliation(s)
- Daniela C Oniciu
- Esperion Therapeutics, A Division of Pfizer Global Research and Development, 3621 South State Street, 695 KMS Place, Ann Arbor, Michigan 48108, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Singh JP, Kauffman R, Bensch W, Wang G, McClelland P, Bean J, Montrose C, Mantlo N, Wagle A. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol Pharmacol 2005; 68:763-8. [PMID: 15933217 DOI: 10.1124/mol.105.010991] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Low high-density lipoprotein-cholesterol (HDL-c) is an important risk factor of coronary artery disease (CAD). Optimum therapy for raising HDL-c is still not available. Identification of novel HDL-raising agents would produce a major impact on CAD. In this study, we have identified a potent (IC50 approximately 24 nM) and selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674). In human apolipoprotein A-1 (apoA-1) transgenic mice, LY518674 produced a dose-dependent increase in serum HDL-c, resulting in 208 +/- 15% elevation at optimum dose. A new synthesis of apoA-1 contributed to the increase in HDL-c. LY518674 increased apoA-1 mRNA levels in liver. Moreover, liver slices from animals treated with LY518674 secreted 3- to 6-fold more apoA-1 than control liver slices. In cultured hepatocytes, LY518674 produced 50% higher apoA-1 secretion, which was associated with increase in radiolabeled methionine incorporation in apoA-1. Thus, LY518674 is a potent and selective PPARalpha agonist that produced a much greater increase in serum HDL-c than the known fibrate drugs. The increase in HDL-c was associated with de novo synthesis of apoA-1.
Collapse
Affiliation(s)
- Jai Pal Singh
- Lilly Research Laboratories, DC:0520, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT. A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia. Mol Endocrinol 2005; 19:1593-605. [PMID: 15831517 DOI: 10.1210/me.2005-0015] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
AbstractLSN862 is a novel peroxisome proliferator-activated receptor (PPAR)α/γ dual agonist with a unique in vitro profile that shows improvements on glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia. Data from in vitro binding, cotransfection, and cofactor recruitment assays characterize LSN862 as a high-affinity PPARγ partial agonist with relatively less but significant PPARα agonist activity. Using these same assays, rosiglitazone was characterized as a high-affinity PPARγ full agonist with no PPARα activity. When administered to Zucker diabetic fatty rats, LSN862 displayed significant glucose and triglyceride lowering and a significantly greater increase in adiponectin levels compared with rosiglitazone. Expression of genes involved in metabolic pathways in the liver and in two fat depots from compound-treated Zucker diabetic fatty rats was evaluated. Only LSN862 significantly elevated mRNA levels of pyruvate dehydrogenase kinase isozyme 4 and bifunctional enzyme in the liver and lipoprotein lipase in both fat depots. In contrast, both LSN862 and rosiglitazone decreased phosphoenol pyruvate carboxykinase in the liver and increased malic enzyme mRNA levels in the fat. In addition, LSN862 was examined in a second rodent model of type 2 diabetes, db/db mice. In this study, LSN862 demonstrated statistically better antidiabetic efficacy compared with rosiglitazone with an equivalent side effect profile. LSN862, rosiglitazone, and fenofibrate were each evaluated in the humanized apoA1 transgenic mouse. At the highest dose administered, LSN862 and fenofibrate reduced very low-density lipoprotein cholesterol, whereas, rosiglitazone increased very low-density lipoprotein cholesterol. LSN862, fenofibrate, and rosiglitazone produced maximal increases in high-density lipoprotein cholesterol of 65, 54, and 30%, respectively. These findings show that PPARγ full agonist activity is not necessary to achieve potent and efficacious insulin-sensitizing benefits and demonstrate the therapeutic advantages of a PPARα/γ dual agonist.
Collapse
MESH Headings
- Adiponectin
- Alkynes/chemistry
- Alkynes/pharmacology
- Animals
- Binding, Competitive
- Body Weight
- Cholesterol/metabolism
- Cholesterol, HDL/metabolism
- Cholesterol, VLDL/metabolism
- Cinnamates/chemistry
- Cinnamates/pharmacology
- Diabetes Mellitus, Experimental/drug therapy
- Diabetes Mellitus, Type 2/drug therapy
- Diabetes Mellitus, Type 2/metabolism
- Dose-Response Relationship, Drug
- Fenofibrate/pharmacology
- Gene Expression Regulation, Enzymologic
- Glucose/metabolism
- Homozygote
- Humans
- Hyperlipidemias/drug therapy
- Hyperlipidemias/metabolism
- In Vitro Techniques
- Insulin/metabolism
- Intercellular Signaling Peptides and Proteins/metabolism
- Kinetics
- Lipid Metabolism
- Liver/enzymology
- Male
- Mice
- Mice, Transgenic
- Models, Chemical
- PPAR alpha/agonists
- PPAR alpha/metabolism
- PPAR gamma/agonists
- PPAR gamma/metabolism
- Protein Binding
- Protein Isoforms
- RNA, Messenger/metabolism
- Rats
- Rosiglitazone
- Thiazolidinediones/pharmacology
- Transfection
- Triglycerides/metabolism
- Two-Hybrid System Techniques
Collapse
Affiliation(s)
- Anne Reifel-Miller
- Endocrinology Division, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Karten B, Hayashi H, Francis G, Campenot R, Vance D, Vance J. Generation and function of astroglial lipoproteins from Niemann-Pick type C1-deficient mice. Biochem J 2005; 387:779-88. [PMID: 15544574 PMCID: PMC1135009 DOI: 10.1042/bj20041694] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2004] [Revised: 11/01/2004] [Accepted: 11/15/2004] [Indexed: 11/17/2022]
Abstract
NPC (Niemann-Pick type C) disease is a progressive neurological disorder characterized by defects in intracellular cholesterol trafficking, accumulation of cholesterol in the endosomal system and impaired cholesterol homoeostasis. Although these alterations appear to occur in all NPC1-deficient cell types, the consequences are most profound in the nervous system. Since glial cells are important mediators of brain cholesterol homoeostasis, we proposed that defective generation and/or function of lipoproteins released by glia might contribute to the neurological abnormalities associated with NPC disease. We found that, as in other cell types, Npc1-/- glia accumulate cholesterol intracellularly. We hypothesized that this sequestration of cholesterol in glia might restrict the availability of cholesterol for lipoprotein production. Cerebellar astroglia were cultured from a murine model of NPC disease to compare the lipoproteins generated by these cells and wild-type glia. The experiments demonstrate that the amount of cholesterol in glia-conditioned medium is not reduced by NPC1 deficiency. Similarly, cholesterol efflux to apo (apolipoprotein) A1 or glial expression of the transporter ATP-binding-cassette transporter A1 was not decreased by NPC1 deficiency. In addition, the ratio of apo E:cholesterol and the density distribution of lipoproteins in Npc1-/- and Npc1+/+ glia-conditioned medium are indistinguishable. Importantly, in a functional assay, apo E-containing lipoproteins generated by Npc1-/- and Npc1+/+ glia each stimulate axonal elongation of neurons by approx. 35%. On the basis of these observations, we speculate that the neuropathology characteristic of NPC disease can quite probably be ascribed to impaired processes within neurons in the brain rather than defective lipoprotein production by astroglia.
Collapse
Key Words
- apo a1
- apo e
- astroglia
- cholesterol secretion
- glial lipoprotein
- niemann–pick type c disease
- abc transporter, atp-binding-cassette transporter
- apo, apolipoprotein
- cns, central nervous system
- csf, cerebrospinal fluid
- dmem, dulbecco's modified eagle's medium
- fbs, fetal bovine serum
- gfap, glial fibrillary acidic protein
- hdl, high-density lipoproteins
- ldl, low-density lipoprotein
- vldl, very low density lipoprotein
- npc, niemann–pick type c
- rgc, retinal ganglion cells
Collapse
Affiliation(s)
- Barbara Karten
- *Canadian Institutes of Health Research Group on the Molecular and Cell Biology of Lipids, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
- †Department of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2S2
| | - Hideki Hayashi
- *Canadian Institutes of Health Research Group on the Molecular and Cell Biology of Lipids, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
- †Department of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2S2
| | - Gordon A. Francis
- *Canadian Institutes of Health Research Group on the Molecular and Cell Biology of Lipids, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
- †Department of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2S2
- ‡Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
| | - Robert B. Campenot
- §Department of Cell Biology, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
| | - Dennis E. Vance
- *Canadian Institutes of Health Research Group on the Molecular and Cell Biology of Lipids, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
- ‡Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
| | - Jean E. Vance
- *Canadian Institutes of Health Research Group on the Molecular and Cell Biology of Lipids, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
- †Department of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2S2
| |
Collapse
|
43
|
Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005; 46:1009-16. [PMID: 15716581 DOI: 10.1194/jlr.m500002-jlr200] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The objective of this study was to demonstrate the efficacy of a novel peroxisome proliferator-activated receptor (PPAR) agonist and known PPARalpha and PPARdelta agonists to increase HDL-cholesterol (HDL-C) in the St. Kitts vervet, a nonhuman primate model of atherosclerosis. Four groups (n = 6) were studied and each group was assigned one of the following "treatments": a) vehicle only (vehicle); b) the PPARdelta selective agonist GW501516 (GW); c) the PPARalpha/delta agonist T913659 (T659); and d) the PPARalpha agonist TriCor (fenofibrate). No statistically significant changes were seen in body weight, total plasma cholesterol, plasma triglycerides, VLDL-C, LDL-C, or apolipoprotein B (apoB) concentrations. Each of the PPARalpha and PPARdelta agonists investigated in this study increased plasma HDL-C, apoA-I, and apoA-II concentrations and increased HDL particle size in St. Kitts vervets. The maximum percentage increase in HDL-C from baseline for each group was as follows: vehicle, 5%; GW, 43%; T659, 43%; and fenofibrate, 20%. Treatment with GW and T659 resulted in an increase in medium-sized HDL particles, whereas fenofibrate showed increases in large HDL particles. These data provide additional evidence that PPARalpha and PPARdelta agonists (both mixed and selective) have beneficial effects on HDL-C in these experimental primates.
Collapse
Affiliation(s)
- Jeanne M Wallace
- Department of Pathology/Comparative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC 27157, USA.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Turk JR, Laughlin MH. Physical activity and atherosclerosis: which animal model? ACTA ACUST UNITED AC 2005; 29:657-83. [PMID: 15536667 DOI: 10.1139/h04-042] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Atherosclerosis is a progressive disease that is the most important single contributor to human cardiovascular morbidity and mortality. Epidemiologic studies show that physical activity, or routine exercise, reduces the risk of developing cardiovascular disease. The mechanisms through which exercise may function in primary or secondary prevention of atherosclerosis remain largely to be established. Most studies in humans are performed after the onset of clinical signs when disease is well advanced and the prescription of exercise is based on empirical evidence of benefit in secondary prevention. Animal models per-mit the study of the initiation and progression of preclinical stages of atherosclerosis. In order to provide information relevant to treatment and prevention, these models should mimic human disease and interactions of physical activity with disease processes as closely as possible. The purpose of this review is to compare animal models of atherosclerosis and to summarize the available data in those models in regard to the effects of exercise.
Collapse
Affiliation(s)
- James R Turk
- Dept. of Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia 65211, USA
| | | |
Collapse
|
45
|
Bell RPL, Verdijk D, Relou M, Smith D, Regeling H, Ebbers EJ, Leemhuis FMC, Oniciu DC, Cramer CT, Goetz B, Pape ME, Krause BR, Bisgaier CL, Dasseux JL. alpha-Cycloalkyl-substituted omega-keto-dicarboxylic acids as lipid regulating agents. Bioorg Med Chem 2005; 13:223-36. [PMID: 15582467 DOI: 10.1016/j.bmc.2004.09.046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2004] [Accepted: 09/23/2004] [Indexed: 11/22/2022]
Abstract
A series of cycloalkyl-substituted oxo-alkanedicarboxylic acids have been prepared by the TosMIC methodology departing from haloalkyl-substituted cycloalkylcarboxylic esters. cyclopropyl derivatives showed IC(50) activity in the 0.3-1.0 microM range on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes, and they showed lipid-regulating properties when tested in vivo in female obese Zucker fatty rats.
Collapse
Affiliation(s)
- Roel P L Bell
- MercaChem BV, Toernooiveld 100, 6525 EC Nijmegen, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Hidiroglou N, Gilani GS, Long L, Zhao X, Madere R, Cockell K, Belonge B, Ratnayake WMN, Peace R. The influence of dietary vitamin E, fat, and methionine on blood cholesterol profile, homocysteine levels, and oxidizability of low density lipoprotein in the gerbil. J Nutr Biochem 2004; 15:730-40. [PMID: 15607646 DOI: 10.1016/j.jnutbio.2004.04.009] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2004] [Accepted: 04/15/2004] [Indexed: 11/23/2022]
Abstract
A 90-day feeding study with gerbils was conducted to evaluate the influence of dietary vitamin E levels (25 mg/kg diet, 75 mg/kg, 300 mg/kg, and 900 mg/kg), two levels of dietary methionione (casein or casein+L-methionine (1% w/w)) and two sources of lipid (soybean oil [20%] or soybean oil [4%]+coconut oil [16%, 1:4 w/w]) upon serum lipids (total cholesterol, HDL-cholesterol, LDL-cholesterol). In addition, this study examined the effects of diet-induced hyperhomocysteinemia and supplemental dietary vitamin E on the oxidation of low density lipoproteins. Tissue vitamin E (heart, liver, and plasma) demonstrated a dose response (P< or =0.001) following the supplementation with increasing dietary vitamin E (25, 75, 300, and 900 mg/kg). In addition, tissue vitamin E levels were found to be higher (P< or =0.001) in those animals receiving a combination of coconut oil+soybean oil as compared to the group receiving soybean oil solely. Blood cholesterol profiles indicated an increase (P< or =0.001) in total cholesterol and LDL cholesterol by the influence of saturated fat and supplemental methionine. Low-density lipoprotein cholesterol profile demonstrated a reduction (P< or =0.001) at the higher dietary vitamin E levels (300 and 900 mg/kg) as compared to the 25 mg/kg and 75 mg/kg dietary vitamin E. Plasma protein carbonyls were not influenced by dietary vitamin E nor by supplemental methionine intake. In vitro oxidation of LDL showed that vitamin E delayed the lag time of the oxidation phase (P< or =0.001) and reduced total diene production (P< or =0.001). On the contrary, supplemental methionine decreased (P< or =0.001) the delay time of the lag phase, whereas total diene production was increased (P< or =0.001). Plasma lipid hydroperoxides were significantly reduced (P< or =0.05) with supplemental dietary vitamin E, whereas supplemental L-methionine (1%) resulted in a significant (P< or =0.05) increase in lipid plasma hydroperoxide formation. Plasma homocysteine was elevated (P< or =0.001) with supplemental dietary L-methionine (1%) as well as the inclusion of dietary saturated fat. The present data showed that 1) a combination of dietary lipids (saturated and unsaturated fatty acids) as well as vitamin E and methionine supplementation altered blood cholesterol lipoprotein profiles; 2) in vitro oxidation parameters including LDL (lag time and diene production) and plasma hydroperoxide formations were affected by vitamin E and methionine supplementation; and 3) plasma homocysteine concentrations were influenced by supplemental methionine and the inclusion of dietary saturated fat.
Collapse
Affiliation(s)
- Nick Hidiroglou
- Nutrition Research Division, Food Directorate, Health Products and Food Branch, Health Canada, Banting Research Centre, Tunneys Pasture, Ottawa, ON, Canada KIAOL2.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110:3465-71. [PMID: 15545514 DOI: 10.1161/01.cir.0000148370.60535.22] [Citation(s) in RCA: 181] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND In clinical studies, sphingomyelin (SM) plasma levels correlated with the occurrence of coronary heart disease independently of plasma cholesterol levels. We hypothesized that inhibition of SM synthesis would have antiatherogenic effects. To test this hypothesis, apolipoprotein E (apoE)-knockout (KO) mice were treated with myriocin, a potent inhibitor of serine palmitoyltransferase, the rate-limiting enzyme in SM biosynthesis. METHODS AND RESULTS Diet-admix treatment of apoE-KO mice with myriocin in Western diet for 12 weeks lowered SM and sphinganine plasma levels. Decreases in sphinganine and SM concentrations were also observed in the liver and aorta of myriocin-treated animals compared with controls. Inhibition of de novo sphingolipid biosynthesis reduced total cholesterol and triglyceride plasma levels. Cholesterol distribution in lipoproteins demonstrated a decrease in beta-VLDL and LDL cholesterol and an increase in HDL cholesterol. Oil red O staining of total aortas demonstrated reduction of atherosclerotic lesion coverage in the myriocin-treated group. Atherosclerotic plaque area was also reduced in the aortic root and brachiocephalic artery. CONCLUSIONS Inhibition of de novo SM biosynthesis in apoE-KO mice lowers plasma cholesterol and triglyceride levels, raises HDL cholesterol, and prevents development of atherosclerotic lesions.
Collapse
Affiliation(s)
- Tae-Sik Park
- Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, Mich 48105, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Mueller R, Yang J, Duan C, Pop E, Geoffroy OJ, Zhang LH, Huang TB, Denisenko S, McCosar BH, Oniciu DC, Bisgaier CL, Pape ME, Freiman CD, Goetz B, Cramer CT, Hopson KL, Dasseux JLH. Long Hydrocarbon Chain Keto Diols and Diacids that Favorably Alter Lipid Disorders in Vivo. J Med Chem 2004; 47:6082-99. [PMID: 15537362 DOI: 10.1021/jm040006p] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Keto-substituted hydrocarbons with 11-19 methylene and bis-terminal hydroxyl and carboxyl groups have been synthesized and evaluated in both in vivo and in vitro assays for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats [Crl:(ZUC)-faBR] following 1 and 2 weeks of oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ketone functionality and the gem dimethyl or methyl/aryl substituents. Furthermore, biological activity was found to be greatest in both in vivo and in vitro assays for the tetramethyl-substituted keto diacids and diols (e.g., 10c, 10g, 14c), and the least active were shown to be the bis(arylmethyl) derivatives (e.g., 10e, 10f, 14f). Compound 14c dose-dependently elevated HDL-cholesterol, reduced triglycerides, and reduced NEFA, with a minimum effective dose of 30 mg/kg/day. Compound 1 g dose-dependently modified non-HDL-cholesterol, triglycerides, and nonesterified fatty acids, with a minimum effective dose of 10 mg/kg/day. At this dose, compound 10g elevated HDL-cholesterol levels 2-3 times higher than pretreatment levels, and a dose-dependent reduction of fasting insulin and glucose levels was observed.
Collapse
Affiliation(s)
- Ralf Mueller
- Alchem Laboratories Corporation, 13305 Rachael Boulevard, Alachua, Florida 32615, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Mueller R, Yang J, Duan C, Pop E, Zhang LH, Huang TB, Denisenko A, Denisko OV, Oniciu DC, Bisgaier CL, Pape ME, Freiman CD, Goetz B, Cramer CT, Hopson KL, Dasseux JLH. Long Hydrocarbon Chain Ether Diols and Ether Diacids That Favorably Alter Lipid Disorders in Vivo. J Med Chem 2004; 47:5183-97. [PMID: 15456261 DOI: 10.1021/jm0400395] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Long hydrocarbon chain ethers with bis-terminal hydroxyl or carboxyl groups have been synthesized and evaluated for their potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes as well as for their effects on lipid and glycemic variables in female obese Zucker fatty rats following 1 and 2 weeks of daily oral administration. The most active compounds were found to be symmetrical with four to five methylene groups separating the central ether functionality and the gem dimethyl or methyl/aryl substituents. Biological activity was found to be greatest for tetramethyl-substituted ether diols (e.g., 28 and 31), while bis(arylmethyl) derivatives (e.g., 10, 11, and 27), diethers (e.g., 49, 50, and 56), and diphenyl ethers (e.g., 35 and 36) were the least active. For the most biologically active compound 28, we observed as much as a 346% increase in serum HDL-cholesterol and a 71% reduction in serum triglycerides at the highest dose administered (100 mg/kg) after 2 weeks of treatment. For compound 31 we observed a 69% reduction in non-HDL-cholesterol, accompanied by a 131% increase in HDL-cholesterol and an 84% reduction in serum triglycerides under the same treatment conditions.
Collapse
Affiliation(s)
- Ralf Mueller
- Alchem Laboratories Corporation, 13305 Rachael Boulevard, Alachua, FL 32615, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Marchesi M, Booth EA, Davis T, Bisgaier CL, Lucchesi BR. Apolipoprotein A-IMilanoand 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury. J Pharmacol Exp Ther 2004; 311:1023-31. [PMID: 15375174 DOI: 10.1124/jpet.104.070789] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Ex vivo studies demonstrated that a synthetic high-density lipoprotein (HDL) comprised of a complex of recombinant apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine protects the isolated rabbit heart from reperfusion injury. Therefore, we sought to determine whether a pharmaceutical preparation of this complex, ETC-216, was cardioprotective in an in vivo model of left anterior descending artery (LAD) occlusion and reperfusion. Initially, ETC-216 (100 mg/kg) was tested in acute (one-treatment) and chronic (two-treatment) i.v. administrations. ETC-216-treated rabbits developed smaller infarcts expressed as percentage of area at risk (p <0.01) compared with vehicle treatments. No differences were noted between chronic and acute administration. Therefore, ETC-216 (10, 3, or 1 mg/kg) or equivalent vehicle volumes were acutely infused. Compared with vehicle, ETC-216 reduced infarct size as a percentage of the area at risk at 10 (p <0.0005) and 3 mg/kg (p <0.05). No significant differences occurred at 1 mg/kg. To determine whether ETC-216 could protect the heart after initiation of ischemia, the synthetic HDL (10 mg/kg) was infused intravenously beginning 5 min before the end of 30 min of LAD occlusion. Infarct size as percentage of the area at risk was 31.6 +/- 3.0 (ETC-216) versus 49.5 +/- 2.5 (vehicle) (p <0.001), and as percentage of left ventricle was 19.7 +/- 1.6 (ETC-216) versus 34.1 +/- 2.3 (vehicle) (p <0.0005). Electron microscopy demonstrated that ETC-216 prevented irreversible cardiac damage as assessed by mitochondrial granulation and sarcomere contraction band formation. These findings suggest ETC-216 reduces reperfusion injury and may have utility for coronary artery revascularization procedures.
Collapse
Affiliation(s)
- Marta Marchesi
- Department of Pharmacology, University of Michigan Medical School, 1301C Medical Science Research Bldg. III, Ann Arbor, MI 48109-0632, USA
| | | | | | | | | |
Collapse
|